Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Page Path

HOME
ARTICLE CATEGORY
Review

Review

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Hwa Kyung Byun, Changhwan Kim, Jinsil Seong

Clin Mol Hepatol. 2023;29(4):945-957. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0217

View: 4094 Download: 121 Web of Science: 9 Crossref: 13

Evidence-based hyponatremia management in liver disease

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):924-944. Published online June 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0090

View: 5594 Download: 309 Web of Science: 7 Crossref: 7

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(4):909-923. Published online May 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0114

View: 4383 Download: 281 Web of Science: 15 Crossref: 16

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0024

View: 10142 Download: 1,364 Web of Science: 9 Crossref: 11

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 4856 Download: 230 Web of Science: 14 Crossref: 20

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka

Clin Mol Hepatol. 2023;29(4):851-868. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0434

View: 9773 Download: 441 Web of Science: 25 Crossref: 22

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 4141 Download: 186 Web of Science: 34 Crossref: 35

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 6859 Download: 405 Web of Science: 63 Crossref: 78

Review

Acute-on-chronic liver failure: Terminology, mechanisms and management

Vinay Kumar BR, Shiv Kumar Sarin

Clin Mol Hepatol. 2023;29(3):670-689. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0103

View: 10078 Download: 915 Web of Science: 29 Crossref: 34

A decade of liver organoids: Advances in disease modeling

Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan

Clin Mol Hepatol. 2023;29(3):643-669. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0428

View: 10989 Download: 350 Web of Science: 10 Crossref: 10

Acute hepatitis C virus infection: clinical update and remaining challenges

Chen-Hua Liu, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):623-642. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0349

View: 8493 Download: 496 Web of Science: 26 Crossref: 28

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2022.0342

View: 7219 Download: 355 Web of Science: 39 Crossref: 42

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 6799 Download: 400 Web of Science: 32 Crossref: 30

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 8756 Download: 480 Web of Science: 44 Crossref: 48

Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications

Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, Beatriz San-Miguel, María J. Tuñón, Javier González-Gallego, José L. Mauriz

Clin Mol Hepatol. 2023;29(2):293-319. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0425

View: 6016 Download: 130 Web of Science: 11 Crossref: 11

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan

Clin Mol Hepatol. 2023;29(2):277-292. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0212

View: 10932 Download: 641 Web of Science: 70 Crossref: 71

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 7065 Download: 357 Web of Science: 21 Crossref: 20

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(2):252-262. Published online March 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0099

View: 6390 Download: 300 Web of Science: 39 Crossref: 41

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 7637 Download: 258 Web of Science: 11 Crossref: 13

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective

Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):230-241. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0421

View: 8353 Download: 411 Web of Science: 21 Crossref: 22

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 7642 Download: 263 Web of Science: 15 Crossref: 16

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 10675 Download: 535 Web of Science: 78 Crossref: 74

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective

Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi

Clin Mol Hepatol. 2023;29(2):197-205. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0404

View: 6178 Download: 261 Web of Science: 20 Crossref: 21

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 9241 Download: 205 Web of Science: 15 Crossref: 18

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 5185 Download: 145 Web of Science: 7 Crossref: 8

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 7447 Download: 319 Web of Science: 28 Crossref: 27

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 6353 Download: 351 Web of Science: 28 Crossref: 28

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 6623 Download: 206 Web of Science: 53 Crossref: 53

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 26030 Download: 1,474 Web of Science: 203 Crossref: 210

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 6846 Download: 277 Web of Science: 24 Crossref: 22

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 10963	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7667	MAFLD: How is it different from NAFLD?
Viewed By 5559	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5017	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4914	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 342	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 316	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes